Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Rhea-AI Summary

Outlook Therapeutics (Nasdaq: OTLK) closed a public offering on March 25, 2026, selling 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares at a combined public offering price of $0.25 per share and warrant.

The offering generated aggregate gross proceeds of $5.0 million before fees; the warrants have a $0.25 exercise price, are exercisable immediately and expire five years from issuance. The company intends to use net proceeds primarily for working capital and general corporate purposes.

Positive

• Raised $5.0 million gross proceeds from common shares and warrants
• Warrants provide potential additional cash of $5.0 million if fully exercised
• Net proceeds earmarked for working capital and general corporate purposes

Negative

• Issued 20,000,000 new common shares, creating immediate dilution
• Up to 20,000,000 warrants exercisable at $0.25 create potential future dilution
• Shares and warrants sold at a combined price of $0.25, indicating low per-share raise

Market Context

This announcement detailed a public offering of 20,000,000 shares plus 20,000,000 warrants at a comb...

Analysis

This announcement detailed a public offering of 20,000,000 shares plus 20,000,000 warrants at a combined price of $0.25, raising gross proceeds of $5.0 million with potential for another $5.0 million from warrant exercises. The company planned to use net proceeds for working capital and general corporate purposes. Investors may focus on how effectively this capital was used relative to the dilution from new shares and long-dated, immediately exercisable warrants.

Key Figures

Shares offered: 20,000,000 shares Warrants offered: 20,000,000 warrants Offering price: $0.25 per share + warrant +5 more

8 metrics

Shares offered 20,000,000 shares Common stock in public offering

Warrants offered 20,000,000 warrants Accompanying common stock offering

Offering price $0.25 per share + warrant Combined public offering price

Warrant exercise price $0.25 per share Exercise price of common warrants

Gross proceeds $5.0 million Aggregate gross proceeds before fees

Potential warrant proceeds $5.0 million If all common warrants exercised for cash

Warrant term 5 years Warrants exercisable immediately, expire five years from issuance

Form S-3 filing date March 28, 2024 Registration statement originally filed with SEC

Key Terms

warrants, exercise price, form s-3, prospectus supplement, +1 more

5 terms

warrants financial

"20,000,000 shares of its common stock and accompanying warrants to purchase..."

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

exercise price financial

"Each common warrant has an exercise price of $0.25 per share..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

form s-3 regulatory

"pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278340)..."

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The public offering was made only by means of a prospectus supplement and an accompanying..."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"prospectus that form a part of the effective registration statement."

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance.

The aggregate gross proceeds of the offering were $5.0 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to Outlook Therapeutics from the common warrants, if fully exercised on a cash basis, will be approximately $5.0 million. No assurance can be given that any of the common warrants will be exercised. Outlook Therapeutics intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The securities described above were offered by Outlook Therapeutics pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and became effective on April 5, 2024. The public offering was made only by means of a prospectus supplement and an accompanying prospectus that form a part of the effective registration statement. A final prospectus supplement and an accompanying prospectus has been filed with the SEC and is available for free on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711, or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements regarding, among others, the expected use of proceeds from the public offering, the potential receipt of additional gross proceeds on exercise of the common warrants, as well as the potential of ONS-5010/LYTENAVA™ as a treatment for retina diseases, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by subsequent reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the global geopolitical conflict, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 908.824.0775

FAQ

What did Outlook Therapeutics (OTLK) announce on March 25, 2026 about a public offering?

The company closed a public offering of 20,000,000 shares and 20,000,000 warrants at $0.25 combined per unit. According to the company, aggregate gross proceeds were $5.0 million before fees and expenses.

How much cash did OTLK raise from the March 25, 2026 offering and how will it be used?

OTLK raised aggregate gross proceeds of $5.0 million before fees. According to the company, net proceeds are intended primarily for working capital and general corporate purposes.

What are the terms of the warrants issued with OTLK shares on March 25, 2026?

Each warrant has an exercise price of $0.25, is exercisable immediately, and expires five years from issuance. According to the company, warrant exercise could provide approximately $5.0 million additional gross proceeds if fully exercised.

Who acted as placement agent for OTLK's March 25, 2026 offering and how were the securities registered?

H.C. Wainwright acted as exclusive placement agent for the offering. According to the company, securities were offered under a Form S-3 shelf registration (File No. 333-278340) that became effective April 5, 2024.

Will exercising the OTLK warrants issued March 25, 2026 immediately dilute current shareholders?

Yes. If warrants are exercised, up to 20,000,000 additional shares could be issued at $0.25, creating further dilution. According to the company, no assurance exists that any warrants will be exercised.

Where can investors find the final prospectus for Outlook Therapeutics' March 25, 2026 offering?

Electronic copies of the final prospectus supplement and accompanying prospectus are available on www.sec.gov. According to the company, printed copies can also be requested from H.C. Wainwright by phone or email.